首页 > 最新文献

Infection and Drug Resistance最新文献

英文 中文
Epidemiology and Mechanism of Drug Resistance of Multidrug-Resistant Klebsiella Pneumoniae Isolated from Patients with Urinary Tract Infection in Beijing Teaching Hospital, China. 北京教学医院尿路感染患者多药耐药肺炎克雷伯菌的流行病学及耐药机制
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S478580
Zeqiang Xie, Jiyong Jian, Liang Chen

Purpose: Klebsiella pneumoniae is an important pathogenic bacterium in causing urinary tract infection. With the overuse of antibiotics, bacteria resistant to quinolones combined with carbapenems are increasing. In this study, we investigated the epidemiology, molecular characteristics, drug resistance of multidrug-resistant Klebsiella pneumoniae (MDR-KPN) isolated from urine samples. It provides theoretical basis for the treatment of urinary tract infection by clinicians.

Patients and methods: Fifty-one strains of Klebsiella pneumonia were obtained from urine samples collected between 2012 and 2017 in total. All the strains are multi-drug resistant bacteria. This paper used multilocus sequence typing (MLST) to determine molecular epidemiological typing. We performed antimicrobial susceptibility testing and investigated quinolones and carbapenems resistance genes.

Results: The strains which we collected were resistant to ciprofloxacin and Levofloxacin. In an epidemiological analysis using MLST, 86.27% (44/51) of isolates were confirmed to be ST11. The main carbapenem resistance gene was KPC-19, 78.43(40/51). Among the quinolone resistance genes, the major resistance genes were aac(6')-Ib-cr, oqxA and oqxB.

Conclusion: The main molecular epidemiological types we detected was ST11. The main resistance gene of carbapenems was KPC-19. The quinolone resistance genes are mainly aac(6')-Ib-cr, oqxA and oqxB. The experimental results can help control the use of quinolones and carbapenems, and we could provide rational drug use basis for clinicians to treat urinary tract infection. For MDR-KPN, a combination of multiple antibiotics is necessary.

目的:肺炎克雷伯菌是引起尿路感染的重要致病菌。随着抗生素的过度使用,对喹诺酮类药物与碳青霉烯类药物联合耐药的细菌正在增加。本研究对尿中分离的耐多药肺炎克雷伯菌(MDR-KPN)的流行病学、分子特征及耐药性进行了研究。为临床医生治疗尿路感染提供理论依据。患者与方法:从2012 - 2017年收集的尿液样本中共检出51株肺炎克雷伯菌。所有菌株均为多重耐药菌。本文采用多位点序列分型(MLST)确定分子流行病学分型。我们进行了药敏试验,并调查了喹诺酮类和碳青霉烯类的耐药基因。结果:所收集的菌株对环丙沙星和左氧氟沙星均有耐药。应用MLST进行流行病学分析,86.27%(44/51)分离株为ST11型。主要耐药基因为KPC-19, 78.43(40/51)。喹诺酮类耐药基因中,主要耐药基因为aac(6′)-Ib-cr、oqxA和oqxB。结论:检测到的分子流行病学类型主要为ST11型。碳青霉烯类主要耐药基因为KPC-19。喹诺酮类耐药基因主要为aac(6′)-Ib-cr、oqxA和oqxB。实验结果有助于控制喹诺酮类药物和碳青霉烯类药物的使用,为临床医生治疗尿路感染提供合理用药依据。对于耐多药- kpn,必须联合使用多种抗生素。
{"title":"Epidemiology and Mechanism of Drug Resistance of Multidrug-Resistant Klebsiella Pneumoniae Isolated from Patients with Urinary Tract Infection in Beijing Teaching Hospital, China.","authors":"Zeqiang Xie, Jiyong Jian, Liang Chen","doi":"10.2147/IDR.S478580","DOIUrl":"10.2147/IDR.S478580","url":null,"abstract":"<p><strong>Purpose: </strong><i>Klebsiella pneumoniae</i> is an important pathogenic bacterium in causing urinary tract infection. With the overuse of antibiotics, bacteria resistant to quinolones combined with carbapenems are increasing. In this study, we investigated the epidemiology, molecular characteristics, drug resistance of multidrug-resistant <i>Klebsiella pneumoniae</i> (<i>MDR-KPN</i>) isolated from urine samples. It provides theoretical basis for the treatment of urinary tract infection by clinicians.</p><p><strong>Patients and methods: </strong>Fifty-one strains of <i>Klebsiella pneumonia</i> were obtained from urine samples collected between 2012 and 2017 in total. All the strains are multi-drug resistant bacteria. This paper used multilocus sequence typing (MLST) to determine molecular epidemiological typing. We performed antimicrobial susceptibility testing and investigated quinolones and carbapenems resistance genes.</p><p><strong>Results: </strong>The strains which we collected were resistant to ciprofloxacin and Levofloxacin. In an epidemiological analysis using MLST, 86.27% (44/51) of isolates were confirmed to be ST11. The main carbapenem resistance gene was KPC-19, 78.43(40/51). Among the quinolone resistance genes, the major resistance genes were aac(6')-Ib-cr, oqxA and oqxB.</p><p><strong>Conclusion: </strong>The main molecular epidemiological types we detected was ST11. The main resistance gene of carbapenems was KPC-19. The quinolone resistance genes are mainly <i>aac(6')-Ib-cr, oqxA and oqxB</i>. The experimental results can help control the use of quinolones and carbapenems, and we could provide rational drug use basis for clinicians to treat urinary tract infection. For <i>MDR-KPN</i>, a combination of multiple antibiotics is necessary.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"135-149"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simultaneous Anti-Tuberculosis and Anti-Tumor Treatment with Immune Checkpoint Inhibitors for Co-Existent Pulmonary Tuberculosis and Advanced Lung Cancer. 用免疫检查点抑制剂同时抗结核和抗肿瘤治疗并存的肺结核和晚期肺癌
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S497006
Huaichong Wang, Liujie Gao, Xinjun Cai, Jinmeng Li, Yuying Lang, Ren Zheng, Shengya Yang

Background: Immune checkpoint inhibitors (ICIs) have emerged as the first-line treatment for driver-negative advanced non-small cell lung cancer (NSCLC). However, there is uncertainty regarding the availability and timing of ICI initiation in patients with NSCLC combined with pulmonary tuberculosis (TB). Additionally, the implementation of dual therapy for anti-TB and anti-tumor treatment poses significant challenges in terms of avoiding drug-drug interactions and reducing adverse reactions during clinical diagnosis and treatment.

Case description: A 65-year-old male patient was admitted to our designated TB hospital following an out-of-hospital TB diagnosis. Relevant examinations were completed after admission, and chest computed tomography revealed that the patient had lung squamous cell carcinoma with multiple metastases in lymph nodes and liver. A multidisciplinary team (MDT) consisting of oncologists, pulmonologists, and clinical pharmacists followed evidence-based practices to determine treatment options. They evaluated the benefits and risks of ICIs and performed therapeutic drug monitoring for the dual treatment of anti-TB and anti-tumor drugs. After 18 days of anti-TB treatment, the patient successfully received ICIs combined with chemotherapy for NSCLC while continuing anti-TB therapy. The patient's anti-TB treatment plan was adjusted due to gastrointestinal reactions, bone marrow suppression, and liver function injury. Ultimately, both NSCLC and pulmonary TB were effectively controlled.

Conclusion: For patients with NSCLC complicated by pulmonary TB, after 2-4 weeks of effective anti-TB treatment, anti-tumor therapies, including ICIs, can be simultaneously implemented with the anti-TB treatment. Therapeutic drug monitoring is beneficial for avoiding serious adverse effects and ensuring the timely treatment of both diseases.

背景:免疫检查点抑制剂(ICIs)已成为驱动阴性晚期非小细胞肺癌(NSCLC)的一线治疗药物。然而,在非小细胞肺癌合并肺结核(TB)患者中,ICI的可用性和起始时间尚不确定。此外,在临床诊断和治疗过程中,实施抗结核和抗肿瘤双重治疗在避免药物相互作用和减少不良反应方面提出了重大挑战。病例描述:一名65岁男性患者在院外结核病诊断后入住我们指定的结核病医院。入院后完成相关检查,胸部ct示肺鳞状细胞癌伴淋巴结及肝脏多发转移。一个由肿瘤学家、肺病学家和临床药剂师组成的多学科小组(MDT)遵循循证实践来确定治疗方案。他们评估了ICIs的益处和风险,并对抗结核和抗肿瘤药物的双重治疗进行了治疗药物监测。经过18天的抗结核治疗,患者在继续抗结核治疗的同时,成功接受了ICIs联合非小细胞肺癌化疗。患者因胃肠道反应、骨髓抑制、肝功能损伤等原因调整抗结核治疗方案。最终,非小细胞肺癌和肺结核被有效控制。结论:对于非小细胞肺癌合并肺结核患者,经过2 ~ 4周有效的抗结核治疗后,可在抗结核治疗的同时实施抗肿瘤治疗,包括ICIs。治疗药物监测有利于避免严重不良反应,确保两种疾病的及时治疗。
{"title":"Simultaneous Anti-Tuberculosis and Anti-Tumor Treatment with Immune Checkpoint Inhibitors for Co-Existent Pulmonary Tuberculosis and Advanced Lung Cancer.","authors":"Huaichong Wang, Liujie Gao, Xinjun Cai, Jinmeng Li, Yuying Lang, Ren Zheng, Shengya Yang","doi":"10.2147/IDR.S497006","DOIUrl":"10.2147/IDR.S497006","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have emerged as the first-line treatment for driver-negative advanced non-small cell lung cancer (NSCLC). However, there is uncertainty regarding the availability and timing of ICI initiation in patients with NSCLC combined with pulmonary tuberculosis (TB). Additionally, the implementation of dual therapy for anti-TB and anti-tumor treatment poses significant challenges in terms of avoiding drug-drug interactions and reducing adverse reactions during clinical diagnosis and treatment.</p><p><strong>Case description: </strong>A 65-year-old male patient was admitted to our designated TB hospital following an out-of-hospital TB diagnosis. Relevant examinations were completed after admission, and chest computed tomography revealed that the patient had lung squamous cell carcinoma with multiple metastases in lymph nodes and liver. A multidisciplinary team (MDT) consisting of oncologists, pulmonologists, and clinical pharmacists followed evidence-based practices to determine treatment options. They evaluated the benefits and risks of ICIs and performed therapeutic drug monitoring for the dual treatment of anti-TB and anti-tumor drugs. After 18 days of anti-TB treatment, the patient successfully received ICIs combined with chemotherapy for NSCLC while continuing anti-TB therapy. The patient's anti-TB treatment plan was adjusted due to gastrointestinal reactions, bone marrow suppression, and liver function injury. Ultimately, both NSCLC and pulmonary TB were effectively controlled.</p><p><strong>Conclusion: </strong>For patients with NSCLC complicated by pulmonary TB, after 2-4 weeks of effective anti-TB treatment, anti-tumor therapies, including ICIs, can be simultaneously implemented with the anti-TB treatment. Therapeutic drug monitoring is beneficial for avoiding serious adverse effects and ensuring the timely treatment of both diseases.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"107-112"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the Impact of tNGS with mNGS on Antimicrobial Management in Patients with LRTIs: A Multicenter Retrospective Cohort Study. 比较tNGS与mNGS对下呼吸道感染患者抗菌管理的影响:一项多中心回顾性队列研究。
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S493575
Dan Li, Qingling Li, Zhen Huang, Wenhao Wu, Xinyuan Fan, Jing Liu, Ruoran Li, Qi Zhang, Xin Su

Background: tNGS and mNGS are valuable tools for diagnosing pathogens in lower respiratory tract infections (LRTIs), which subsequently influence treatment strategies. However, the impact of tNGS and mNGS on antimicrobial stewardship in patients with LRTIs remains unclear.

Methods: Patients diagnosed with LRTIs who underwent tNGS or mNGS between June 2021 and January 2024 were included. Patients who underwent both tNGS and conventional microbiologic tests (CMTs) were grouped into the tNGS group, the others were divided into the mNGS group. Then, the diagnostic efficacy of tNGS and mNGS was compared, along with their impact on antimicrobial management and clinical outcomes.

Results: 548 patients with an initial diagnosis of LRTIs who underwent tNGS or mNGS were evaluated. Finally, 321 patients were analyzed, with 117 patients in tNGS group and 204 patients in mNGS group. The overall pathogen detection rates for tNGS and mNGS were 89.74% and 89.71% (P=0.991). The distribution of detected pathogens was similar between tNGS and mNGS, with bacteria being the predominant microorganisms. The proportions of patients who underwent antimicrobial agent changes and received targeted therapy were not significantly different between tNGS and mNGS groups (P=0.270; P=0.893). Additionally, no significant differences were noted in the rates of antibiotic de-escalation, escalation, or changes in the opposite direction (all P>0.05). The same results was observed in the proportions of patients with addition or reductions in antiviral, antifungal, and antibacterial agents (all P>0.05). Hospital stays, improvement rate and mortality rate were also similar (all P>0.05).

Conclusion: tNGS and mNGS demonstrate comparable overall pathogen yield rates in patients with LRTIs. Furthermore, tNGS is also comparable to mNGS in terms of adjusting antimicrobial treatments and clinical outcomes, tNGS meets the clinical needs of most patients with LRTIs and can be firstly used for these patients.

背景:tNGS和mNGS是诊断下呼吸道感染(LRTIs)病原体的有价值的工具,从而影响治疗策略。然而,tNGS和mNGS对下呼吸道感染患者抗菌药物管理的影响尚不清楚。方法:纳入2021年6月至2024年1月期间接受tNGS或mNGS的诊断为下呼吸道炎的患者。同时接受tNGS和常规微生物学测试(CMTs)的患者分为tNGS组,其他患者分为mNGS组。然后比较tNGS和mNGS的诊断效果,以及它们对抗菌药物管理和临床结果的影响。结果:548例初步诊断为下呼吸道炎的患者接受了tNGS或mNGS评估。最终对321例患者进行分析,其中tNGS组117例,mNGS组204例。tNGS和mNGS的总检出率分别为89.74%和89.71% (P=0.991)。检测到的病原菌在tNGS和mNGS之间分布相似,以细菌为优势微生物。tNGS组和mNGS组患者更换抗菌药物和接受靶向治疗的比例差异无统计学意义(P=0.270;P = 0.893)。此外,没有显著差异指出利率的抗生素降级,升级,或者相反方向的变化(P > 0.05)。在增加或减少抗病毒、抗真菌和抗菌药物的患者比例中观察到相同的结果(均P < 0.05)。两组住院时间、治愈率和死亡率相似(P < 0.05)。结论:tNGS和mNGS在下呼吸道感染患者中表现出相当的总体病原体产率。此外,tNGS在调整抗菌治疗和临床结局方面也与mNGS相当,tNGS满足大多数下呼吸道感染患者的临床需求,可率先用于下呼吸道感染患者。
{"title":"Comparison of the Impact of tNGS with mNGS on Antimicrobial Management in Patients with LRTIs: A Multicenter Retrospective Cohort Study.","authors":"Dan Li, Qingling Li, Zhen Huang, Wenhao Wu, Xinyuan Fan, Jing Liu, Ruoran Li, Qi Zhang, Xin Su","doi":"10.2147/IDR.S493575","DOIUrl":"10.2147/IDR.S493575","url":null,"abstract":"<p><strong>Background: </strong>tNGS and mNGS are valuable tools for diagnosing pathogens in lower respiratory tract infections (LRTIs), which subsequently influence treatment strategies. However, the impact of tNGS and mNGS on antimicrobial stewardship in patients with LRTIs remains unclear.</p><p><strong>Methods: </strong>Patients diagnosed with LRTIs who underwent tNGS or mNGS between June 2021 and January 2024 were included. Patients who underwent both tNGS and conventional microbiologic tests (CMTs) were grouped into the tNGS group, the others were divided into the mNGS group. Then, the diagnostic efficacy of tNGS and mNGS was compared, along with their impact on antimicrobial management and clinical outcomes.</p><p><strong>Results: </strong>548 patients with an initial diagnosis of LRTIs who underwent tNGS or mNGS were evaluated. Finally, 321 patients were analyzed, with 117 patients in tNGS group and 204 patients in mNGS group. The overall pathogen detection rates for tNGS and mNGS were 89.74% and 89.71% (<i>P</i>=0.991). The distribution of detected pathogens was similar between tNGS and mNGS, with bacteria being the predominant microorganisms. The proportions of patients who underwent antimicrobial agent changes and received targeted therapy were not significantly different between tNGS and mNGS groups (<i>P</i>=0.270; <i>P</i>=0.893). Additionally, no significant differences were noted in the rates of antibiotic de-escalation, escalation, or changes in the opposite direction (all <i>P</i>>0.05). The same results was observed in the proportions of patients with addition or reductions in antiviral, antifungal, and antibacterial agents (all <i>P</i>>0.05). Hospital stays, improvement rate and mortality rate were also similar (all <i>P</i>>0.05).</p><p><strong>Conclusion: </strong>tNGS and mNGS demonstrate comparable overall pathogen yield rates in patients with LRTIs. Furthermore, tNGS is also comparable to mNGS in terms of adjusting antimicrobial treatments and clinical outcomes, tNGS meets the clinical needs of most patients with LRTIs and can be firstly used for these patients.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"93-105"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Outcomes of a Health Information System-Based Feedback Intervention Study of Antimicrobial Prescriptions in Primary Care Institutions: Follow-Up of a Randomized Cross-Over Controlled Trial. 基于卫生信息系统的初级保健机构抗菌药物处方反馈干预研究的长期结果:一项随机交叉对照试验的随访。
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S492367
Yuxing Yan, Junli Yang, Yun Lu, Zhezhe Cui, Yue Chang

Purpose: To evaluate the long-term impacts of the feedback intervention on controlling inappropriate use of antimicrobial prescriptions in primary care institutions in China, as a continuation of the previous feedback intervention trial.

Methods: After the intervention ended, we conducted a 12-month follow-up study. The prescription data were collected from the baseline until the end of the follow-up period. The generalized estimation equation was employed to analyze the differences among four representative time points: at the baseline point, at 3 months, at 6 months, and at 18 months. The time-intervention interaction was utilized to evaluate the changing trends of group A and group B. Our primary outcome variable is the monthly inappropriate antimicrobial prescription rate (IAPR).

Results: After adjusting for covariates, the IAPRs in group A decreased by 1.00% on average from the baseline point to the 3 months, 5.00% from the 3 months to the 6 months, -0.92% from the 6 months to the 18 months, and 0.39% from the baseline point to the 18 months. During the corresponding four periods in group B, the average decline was 2.33%, 3.67%, -0.42%, and 0.72%, respectively. As for antimicrobial prescription rates (APRs), the average decline for group A was 1.33%, 3.67%, and 0.17% during the three periods: from the baseline point to the 3 months, from the 3 months to the 6 months, and from the 6 months to the 18 months, respectively. Accordingly in group B, the average decline was 1.00%, 3.67%, and 0.08%, respectively.

Conclusion: Our feedback intervention generated limited long-term impacts. Although the IAPRs and the APRs consistently remained below the baseline point, both rates experienced a rebound within a certain range following the stop of the intervention in the two groups. It is reasonable to think that the desired effects will be difficult to maintain without sustained implementation of feedback intervention.

目的:作为之前反馈干预试验的延续,评估反馈干预对控制中国基层医疗机构抗菌药物处方不当使用的长期影响。方法:干预结束后,进行为期12个月的随访研究。处方数据从基线收集到随访期结束。采用广义估计方程分析基线点、3个月、6个月和18个月四个代表性时间点的差异。采用时间干预交互作用评价A组和b组的变化趋势。我们的主要结局变量是每月不适当抗菌药物处方率(IAPR)。结果:经协变量调整后,A组iapr从基线点到3个月平均下降1.00%,从3个月到6个月平均下降5.00%,从6个月到18个月平均下降-0.92%,从基线点到18个月平均下降0.39%。B组相应4个时期平均下降率分别为2.33%、3.67%、-0.42%、0.72%。在抗菌药物处方率(APRs)方面,A组在基线点至第3个月、第3个月至第6个月、第6个月至第18个月期间平均下降1.33%、3.67%和0.17%。B组平均下降率分别为1.00%、3.67%、0.08%。结论:我们的反馈干预产生了有限的长期影响。虽然iapr和apr一直保持在基线点以下,但在两组干预停止后,这两个比率都在一定范围内反弹。我们有理由认为,如果不持续实施反馈干预,预期的效果将难以维持。
{"title":"Long-Term Outcomes of a Health Information System-Based Feedback Intervention Study of Antimicrobial Prescriptions in Primary Care Institutions: Follow-Up of a Randomized Cross-Over Controlled Trial.","authors":"Yuxing Yan, Junli Yang, Yun Lu, Zhezhe Cui, Yue Chang","doi":"10.2147/IDR.S492367","DOIUrl":"10.2147/IDR.S492367","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the long-term impacts of the feedback intervention on controlling inappropriate use of antimicrobial prescriptions in primary care institutions in China, as a continuation of the previous feedback intervention trial.</p><p><strong>Methods: </strong>After the intervention ended, we conducted a 12-month follow-up study. The prescription data were collected from the baseline until the end of the follow-up period. The generalized estimation equation was employed to analyze the differences among four representative time points: at the baseline point, at 3 months, at 6 months, and at 18 months. The time-intervention interaction was utilized to evaluate the changing trends of group A and group B. Our primary outcome variable is the monthly inappropriate antimicrobial prescription rate (IAPR).</p><p><strong>Results: </strong>After adjusting for covariates, the IAPRs in group A decreased by 1.00% on average from the baseline point to the 3 months, 5.00% from the 3 months to the 6 months, -0.92% from the 6 months to the 18 months, and 0.39% from the baseline point to the 18 months. During the corresponding four periods in group B, the average decline was 2.33%, 3.67%, -0.42%, and 0.72%, respectively. As for antimicrobial prescription rates (APRs), the average decline for group A was 1.33%, 3.67%, and 0.17% during the three periods: from the baseline point to the 3 months, from the 3 months to the 6 months, and from the 6 months to the 18 months, respectively. Accordingly in group B, the average decline was 1.00%, 3.67%, and 0.08%, respectively.</p><p><strong>Conclusion: </strong>Our feedback intervention generated limited long-term impacts. Although the IAPRs and the APRs consistently remained below the baseline point, both rates experienced a rebound within a certain range following the stop of the intervention in the two groups. It is reasonable to think that the desired effects will be difficult to maintain without sustained implementation of feedback intervention.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"61-76"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Artificial Liver Support System and Prognosis in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. 人工肝支持系统与乙型肝炎病毒相关性急慢性肝衰竭患者预后的关系
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S500291
Kunping Cui, Chang-Hai Liu, Xiangnan Teng, Fang Chen, Yan Xu, Shaoqun Zhou, Qi Yang, Lingyao Du, YuanJi Ma, Lang Bai

Objective: The artificial liver support system (ALSS) has been recruited as an available method for patients with acute-on-chronic liver failure (ACLF), but its impact on the outcome of ACLF remains controversial. This study aimed to investigate the association between ALSS treatment and short-term prognosis of hepatitis B-related ACLF (HBV-ACLF).

Methods: This was a retrospective observational cohort study, and data were obtained from the Center of Infectious Diseases, West China Hospital of Sichuan University, between Mar 2015 and December 2021. The primary outcome was 28-day transplant-free mortality and the secondary outcomes were 60- and 90-day transplant-free mortality. Patients were divided into standard medical therapy (SMT) and ALSS groups. Kaplan-Meier survival analysis curves show the 28-day, 60-day and 90-day transplant-free mortality. Based on the feature selection result of univariate logistic, univariate Cox and Boruta algorithm, the univariate and multivariate logistic and COX regression models were used to investigate the association of ALSS with 28-day, 60-day and 90-day outcomes in patients with HBV-ACLF. Subgroup analyses were conducted to test the robustness of the results.

Results: A total of 589 hBV-ACLF patients were enrolled in this study (median age, 48.00 years [IQR,44.00-55.00 years]; 70 [11.9%] female). The 28-day, 60-day and 90-day transplant-free mortality rates were 25.6%, 35.8% and 38.9%, respectively. In the univariate and Kaplan-Meier survival analysis, ALSS could significantly reduce 28-day, 60-day and 90-day transplant-free mortality compared to SMT. Furthermore, an in-depth analysis of our study revealed that the therapeutic benefits of the ALSS were observed exclusively within the end-stage (PT-INR ≥ 2.5) subgroup of HBV-ACLF patients.

Conclusion: Compared to SMT, ALSS demonstrated efficacy primarily in enhancing the short- term prognosis of end-stage HBV-ACLF patients, rather than across the entire spectrum of HBV-ACLF patients.

目的:人工肝支持系统(ALSS)已被作为急性-慢性肝衰竭(ACLF)患者的一种可用方法,但其对ACLF预后的影响仍存在争议。本研究旨在探讨 ALSS 治疗与乙肝相关 ACLF(HBV-ACLF)短期预后之间的关系:这是一项回顾性队列研究,数据来自四川大学华西医院传染病中心,时间为2015年3月至2021年12月。主要结果为28天无移植死亡率,次要结果为60天和90天无移植死亡率。患者分为标准药物治疗组(SMT)和ALSS组。Kaplan-Meier 生存分析曲线显示了 28 天、60 天和 90 天无移植死亡率。根据单变量 logistic、单变量 Cox 和 Boruta 算法的特征选择结果,使用单变量和多变量 logistic 及 COX 回归模型研究 ALSS 与 HBV-ACLF 患者 28 天、60 天和 90 天预后的相关性。为检验结果的稳健性,还进行了分组分析:共有 589 名 HBV-ACLF 患者参与了这项研究(中位年龄 48.00 岁 [IQR,44.00-55.00岁];女性 70 [11.9%])。28天、60天和90天无移植死亡率分别为25.6%、35.8%和38.9%。在单变量和 Kaplan-Meier 生存分析中,与 SMT 相比,ALSS 可显著降低 28 天、60 天和 90 天无移植死亡率。此外,对我们研究的深入分析显示,ALSS的治疗效果仅在HBV-ACLF患者的终末期(PT-INR≥2.5)亚组中观察到:结论:与 SMT 相比,ALSS 主要在改善 HBV-ACLF 终末期患者的短期预后方面表现出疗效,而不是在整个 HBV-ACLF 患者中表现出疗效。
{"title":"Association Between Artificial Liver Support System and Prognosis in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.","authors":"Kunping Cui, Chang-Hai Liu, Xiangnan Teng, Fang Chen, Yan Xu, Shaoqun Zhou, Qi Yang, Lingyao Du, YuanJi Ma, Lang Bai","doi":"10.2147/IDR.S500291","DOIUrl":"10.2147/IDR.S500291","url":null,"abstract":"<p><strong>Objective: </strong>The artificial liver support system (ALSS) has been recruited as an available method for patients with acute-on-chronic liver failure (ACLF), but its impact on the outcome of ACLF remains controversial. This study aimed to investigate the association between ALSS treatment and short-term prognosis of hepatitis B-related ACLF (HBV-ACLF).</p><p><strong>Methods: </strong>This was a retrospective observational cohort study, and data were obtained from the Center of Infectious Diseases, West China Hospital of Sichuan University, between Mar 2015 and December 2021. The primary outcome was 28-day transplant-free mortality and the secondary outcomes were 60- and 90-day transplant-free mortality. Patients were divided into standard medical therapy (SMT) and ALSS groups. Kaplan-Meier survival analysis curves show the 28-day, 60-day and 90-day transplant-free mortality. Based on the feature selection result of univariate logistic, univariate Cox and Boruta algorithm, the univariate and multivariate logistic and COX regression models were used to investigate the association of ALSS with 28-day, 60-day and 90-day outcomes in patients with HBV-ACLF. Subgroup analyses were conducted to test the robustness of the results.</p><p><strong>Results: </strong>A total of 589 hBV-ACLF patients were enrolled in this study (median age, 48.00 years [IQR,44.00-55.00 years]; 70 [11.9%] female). The 28-day, 60-day and 90-day transplant-free mortality rates were 25.6%, 35.8% and 38.9%, respectively. In the univariate and Kaplan-Meier survival analysis, ALSS could significantly reduce 28-day, 60-day and 90-day transplant-free mortality compared to SMT. Furthermore, an in-depth analysis of our study revealed that the therapeutic benefits of the ALSS were observed exclusively within the end-stage (PT-INR ≥ 2.5) subgroup of HBV-ACLF patients.</p><p><strong>Conclusion: </strong>Compared to SMT, ALSS demonstrated efficacy primarily in enhancing the short- term prognosis of end-stage HBV-ACLF patients, rather than across the entire spectrum of HBV-ACLF patients.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"113-126"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Characterization and Risk Factors of Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae Isolated from Chinese Tertiary Hospital. 中国三级医院耐碳青霉烯高毒力肺炎克雷伯菌分子特征及危险因素分析
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S494208
Rongping Zhu, Ju Li, Siyan Lian, Yishan Li, Meili Cai, Yingping Cao, Xiaohong Xu

Background: Therefore, the objectives of this study were to investigate the prevalence of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKp) in Fujian Medical University Union Hospital, identify their genetic characters, characterize their resistance profiles, and identify risk factors for their infection to improve prevention and treatment strategies for CR-hvKp in the area.

Methods: Between January 2021 and January 2022, clinically identified carbapenem-resistant Klebsiella pneumoniae (CRKp) isolates were collected. A PCR assay was used to detect the K capsule type, virulence genes, carbapenemase genes, and membrane pore protein. ERIC-PCR was carried out for homology analysis. Antimicrobial susceptibility test was used to determine drug resistance. Logistic multivariate regression analysis was conducted to confirm the risk factors for CR-hvKp infection.

Results: In total, 239 CRKp isolates were obtained. The virulence genes with the highest detection rates were mrkD, iucA, and rmpA2. Of these isolates, 54 (22.59%) carried both iucA and rmpA2, thus classifying them as CR-hvKp. All CR-hvKp isolates carried bla KPC. Furthermore, capsular serotypes K64 (94.44%) and K47 (3.70%) were detected. Resistance was observed against most common antibiotics, with the exception of complete sensitivity to ceftazidime-avibactam. ERIC-PCR indicated a potential clonal spread among CR-hvKp. Multivariate analysis found that changing beds was a risk factor for CR-hvKp infection.

Conclusion: Currently, the hospital predominantly carries K64 CR-hvKp that harbors the bla KPC. Our study found that changing patient beds was an independent risk factor for CR-hvKp infection.

背景:本研究旨在调查福建医科大学协和医院耐碳青霉烯类高毒力肺炎克雷伯菌(CR-hvKp)的流行情况,确定其遗传特征、耐药特征,并确定其感染的危险因素,以改进该地区CR-hvKp的防治策略。方法:收集2021年1月至2022年1月期间临床鉴定的耐碳青霉烯肺炎克雷伯菌(CRKp)分离株。采用PCR法检测K囊型、毒力基因、碳青霉烯酶基因和膜孔蛋白。采用ERIC-PCR进行同源性分析。采用药敏试验测定耐药情况。采用Logistic多因素回归分析确定感染CR-hvKp的危险因素。结果:共分离得到239株CRKp。检出率最高的毒力基因为mrkD、iucA和rmpA2。在这些分离株中,54株(22.59%)同时携带iucA和rmpA2,从而将其归类为CR-hvKp。所有CR-hvKp分离株均携带bla KPC。检出荚膜血清型K64(94.44%)和K47(3.70%)。除对头孢他啶-阿维巴坦完全敏感外,对大多数常见抗生素均有耐药性。ERIC-PCR显示在CR-hvKp中存在潜在的克隆传播。多因素分析发现换床是感染CR-hvKp的危险因素。结论:目前医院主要携带含有bla KPC的K64 CR-hvKp。我们的研究发现,更换病床是感染CR-hvKp的独立危险因素。
{"title":"Molecular Characterization and Risk Factors of Carbapenem-Resistant Hypervirulent <i>Klebsiella pneumoniae</i> Isolated from Chinese Tertiary Hospital.","authors":"Rongping Zhu, Ju Li, Siyan Lian, Yishan Li, Meili Cai, Yingping Cao, Xiaohong Xu","doi":"10.2147/IDR.S494208","DOIUrl":"10.2147/IDR.S494208","url":null,"abstract":"<p><strong>Background: </strong>Therefore, the objectives of this study were to investigate the prevalence of carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> (CR-hvKp) in Fujian Medical University Union Hospital, identify their genetic characters, characterize their resistance profiles, and identify risk factors for their infection to improve prevention and treatment strategies for CR-hvKp in the area.</p><p><strong>Methods: </strong>Between January 2021 and January 2022, clinically identified carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKp) isolates were collected. A PCR assay was used to detect the K capsule type, virulence genes, carbapenemase genes, and membrane pore protein. ERIC-PCR was carried out for homology analysis. Antimicrobial susceptibility test was used to determine drug resistance. Logistic multivariate regression analysis was conducted to confirm the risk factors for CR-hvKp infection.</p><p><strong>Results: </strong>In total, 239 CRKp isolates were obtained. The virulence genes with the highest detection rates were <i>mrkD, iucA</i>, and <i>rmpA2</i>. Of these isolates, 54 (22.59%) carried both <i>iucA</i> and <i>rmpA2</i>, thus classifying them as CR-hvKp. All CR-hvKp isolates carried <i>bla</i> <sub>KPC</sub>. Furthermore, capsular serotypes K64 (94.44%) and K47 (3.70%) were detected. Resistance was observed against most common antibiotics, with the exception of complete sensitivity to ceftazidime-avibactam. ERIC-PCR indicated a potential clonal spread among CR-hvKp. Multivariate analysis found that changing beds was a risk factor for CR-hvKp infection.</p><p><strong>Conclusion: </strong>Currently, the hospital predominantly carries K64 CR-hvKp that harbors the <i>bla</i> <sub>KPC</sub>. Our study found that changing patient beds was an independent risk factor for CR-hvKp infection.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"83-92"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Necrotizing Bronchitis with Airway Obstruction Due to Macrolide-Resistant Mycoplasma pneumoniae in a Child: A Case Report. 儿童大环内酯耐药肺炎支原体所致坏死性支气管炎伴气道阻塞1例。
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S498411
Zhongjie Li, Yao Xu, Yujian Xiang

Although infection with Mycoplasma pneumoniae is generally self-limited, it may cause refractory or life-threatening pneumonia with pulmonary or extrapulmonary complications. Necrotizing bronchitis is a rare condition with a high mortality rate. The present report describes a patient with mycoplasma pneumonia and necrotizing bronchitis that caused airway obstruction. A 7-year-old girl presented with fever and cough and was hospitalized. Her symptoms did not improve, and mild hypoxemia was observed. Fiberoptic bronchoscopy revealed diffuse bronchitis with necrotic and hemorrhagic material obstructing the bronchus. The necrotic tissue was removed directly, unblocking the airways. This case underscores the importance of fiberoptic bronchoscopy for early diagnosis and treatment of severe respiratory complications associated with Mycoplasma pneumoniae infection, such as necrotizing bronchitis. Early recognition and timely intervention are critical to improving patient outcomes in such cases.

虽然肺炎支原体感染通常是自限性的,但它可能引起难治性或危及生命的肺炎,并伴有肺或肺外并发症。坏死性支气管炎是一种罕见的疾病,死亡率很高。本报告描述了一个患者与支原体肺炎和坏死性支气管炎,引起气道阻塞。一名7岁女孩出现发烧和咳嗽并住院。她的症状没有改善,并观察到轻度低氧血症。纤维支气管镜检查显示弥漫性支气管炎,坏死和出血性物质阻塞支气管。直接切除坏死组织,疏通气道。本病例强调了纤维支气管镜对肺炎支原体感染相关的严重呼吸道并发症(如坏死性支气管炎)的早期诊断和治疗的重要性。在这种情况下,早期识别和及时干预对改善患者预后至关重要。
{"title":"Necrotizing Bronchitis with Airway Obstruction Due to Macrolide-Resistant <i>Mycoplasma pneumoniae</i> in a Child: A Case Report.","authors":"Zhongjie Li, Yao Xu, Yujian Xiang","doi":"10.2147/IDR.S498411","DOIUrl":"10.2147/IDR.S498411","url":null,"abstract":"<p><p>Although infection with <i>Mycoplasma pneumoniae</i> is generally self-limited, it may cause refractory or life-threatening pneumonia with pulmonary or extrapulmonary complications. Necrotizing bronchitis is a rare condition with a high mortality rate. The present report describes a patient with mycoplasma pneumonia and necrotizing bronchitis that caused airway obstruction. A 7-year-old girl presented with fever and cough and was hospitalized. Her symptoms did not improve, and mild hypoxemia was observed. Fiberoptic bronchoscopy revealed diffuse bronchitis with necrotic and hemorrhagic material obstructing the bronchus. The necrotic tissue was removed directly, unblocking the airways. This case underscores the importance of fiberoptic bronchoscopy for early diagnosis and treatment of severe respiratory complications associated with Mycoplasma pneumoniae infection, such as necrotizing bronchitis. Early recognition and timely intervention are critical to improving patient outcomes in such cases.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"77-82"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The First Case of Candida auris Detection and Infection Control in a Pediatric Bone Marrow Transplant Child Patient in Guangxi, China. 广西首例小儿骨髓移植患者耳念珠菌检测及感染控制。
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S490696
Liu Yang, Kaiting Hong, Jiajia Luo, Lili Wang, Lei Zhang, Lijun Jiang, Qiliu Peng, Jian Guo

Candida auris is an emerging yeast species and an opportunistic pathogen. Due to its multi-drug resistance and ability to colonize and transmit, it poses a significant risk for outbreaks in medical institutions. In this study, we report the first case of C. auris detected in a pediatric bone marrow transplant child patient in Guangxi, China. C. auris was isolated from urine and identified using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry, and the isolate belonged to clade I using sequencing. We have implemented stringent infection control measures including personal protective equipment and treatment in a single room, and conducted regular surveillance screening of patients' body surfaces, as well as those of related medical and logistics personnel, medical equipment, and surrounding environmental surfaces. These measures aim to effectively control the colonization of C. auris in patients, prevent its spread within hospitals, and ensure the quality of diagnosis and treatment for patients.

耳念珠菌是一种新兴的酵母菌,是一种机会致病菌。由于其多重耐药性以及定植和传播能力,它对医疗机构的爆发构成了重大风险。在这项研究中,我们报告了在中国广西的一名儿童骨髓移植患者中发现的第一例耳念珠菌。采用基质辅助激光解吸电离飞行时间(MALDI-TOF)质谱法对尿中金黄色葡萄球菌(C. auris)进行了分离鉴定,经测序,该分离物属于I枝。我们严格执行个人防护装备、单间治疗等感染控制措施,定期对患者体表、相关医疗后勤人员体表、医疗设备、周边环境表面进行监测筛查。这些措施的目的是有效地控制患者c .耳的殖民化,防止医院内传播,并确保对患者诊断和治疗的质量。
{"title":"The First Case of <i>Candida auris</i> Detection and Infection Control in a Pediatric Bone Marrow Transplant Child Patient in Guangxi, China.","authors":"Liu Yang, Kaiting Hong, Jiajia Luo, Lili Wang, Lei Zhang, Lijun Jiang, Qiliu Peng, Jian Guo","doi":"10.2147/IDR.S490696","DOIUrl":"10.2147/IDR.S490696","url":null,"abstract":"<p><p><i>Candida auris</i> is an emerging yeast species and an opportunistic pathogen. Due to its multi-drug resistance and ability to colonize and transmit, it poses a significant risk for outbreaks in medical institutions. In this study, we report the first case of <i>C. auris</i> detected in a pediatric bone marrow transplant child patient in Guangxi, China. <i>C. auris</i> was isolated from urine and identified using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry, and the isolate belonged to clade I using sequencing. We have implemented stringent infection control measures including personal protective equipment and treatment in a single room, and conducted regular surveillance screening of patients' body surfaces, as well as those of related medical and logistics personnel, medical equipment, and surrounding environmental surfaces. These measures aim to effectively control the colonization of <i>C. auris</i> in patients, prevent its spread within hospitals, and ensure the quality of diagnosis and treatment for patients.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"127-133"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aggressive Infection by K1/ST1265 Klebsiella pneumoniae Leading to Multiple Abscesses: Case Report and Literature Review. K1/ST1265肺炎克雷伯菌侵袭性感染导致多发性脓肿:病例报告及文献复习
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-03 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S489161
Lina Chen, Canhu Qiu, Ye Lu, Jianqing Lin, Liping Xu

Hypervirulent Klebsiella pneumoniae (hvKp) has attracted increasing attention in recent years. Diabetes and serotype K1 or K2 are risk factors for invasive liver abscess syndrome including liver abscesses and the metastatic complications such as bacteremia, meningitis, endophthalmitis, and necrotizing fasciitis. Simultaneous infections of the liver, lungs, prostate, brain, and eyes are exceedingly rare. In this paper, a 41-year-old male patient who presented with a 4-day history of fever with polydipsia and polyuria and untreated diabetes deteriorated dramatically with sepsis, prostate abscess, lung abscess, liver abscess and intracranial infection as well as endophthalmitis. He was diagnosed with infection by K1/ST1265 hypervirulent Klebsiella pneumoniae and after treatment with antibiotics and abscess drainage, while the patient still passed away. K1/ST1265 hvKp exhibits exceptionally high virulence and invasiveness, necessitating broad awareness and vigilant monitoring.

近年来,高致病性肺炎克雷伯菌(hvKp)引起了越来越多的关注。糖尿病和血清型K1或K2是侵袭性肝脓肿综合征的危险因素,包括肝脓肿和转移性并发症,如菌血症、脑膜炎、眼内炎和坏死性筋膜炎。同时感染肝、肺、前列腺、脑和眼睛的情况极为罕见。本文报道一名41岁男性患者,有发热伴多饮多尿4天病史,糖尿病未经治疗后病情急剧恶化,并发脓毒症、前列腺脓肿、肺脓肿、肝脓肿、颅内感染及眼内炎。确诊为K1/ST1265高毒力肺炎克雷伯菌感染,经抗生素和脓肿引流治疗,患者仍然死亡。K1/ST1265 hvKp表现出异常高的毒力和侵袭性,需要广泛的认识和警惕的监测。
{"title":"Aggressive Infection by K1/ST1265 <i>Klebsiella pneumoniae</i> Leading to Multiple Abscesses: Case Report and Literature Review.","authors":"Lina Chen, Canhu Qiu, Ye Lu, Jianqing Lin, Liping Xu","doi":"10.2147/IDR.S489161","DOIUrl":"https://doi.org/10.2147/IDR.S489161","url":null,"abstract":"<p><p>Hypervirulent <i>Klebsiella pneumoniae</i> (hvKp) has attracted increasing attention in recent years. Diabetes and serotype K1 or K2 are risk factors for invasive liver abscess syndrome including liver abscesses and the metastatic complications such as bacteremia, meningitis, endophthalmitis, and necrotizing fasciitis. Simultaneous infections of the liver, lungs, prostate, brain, and eyes are exceedingly rare. In this paper, a 41-year-old male patient who presented with a 4-day history of fever with polydipsia and polyuria and untreated diabetes deteriorated dramatically with sepsis, prostate abscess, lung abscess, liver abscess and intracranial infection as well as endophthalmitis. He was diagnosed with infection by K1/ST1265 hypervirulent <i>Klebsiella pneumoniae</i> and after treatment with antibiotics and abscess drainage, while the patient still passed away. K1/ST1265 hvKp exhibits exceptionally high virulence and invasiveness, necessitating broad awareness and vigilant monitoring.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"43-49"},"PeriodicalIF":2.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Etiology, Risk Factors, and Antimicrobial Resistance in Recurrent Pyogenic Liver Abscesses: A Six-Year Analysis. 复发性化脓性肝脓肿的病因、危险因素和抗菌素耐药性:六年分析。
IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-01-03 eCollection Date: 2025-01-01 DOI: 10.2147/IDR.S492544
JinHua Cui, YaMan Liu, Hua Fu, MiaoHang Cui, JiZhong Li, ZiYu Bai, Jian Li

Aim: To perform a comparative analysis of the clinical data of patients with and without recurrent pyogenic liver abscess and explore the influencing factors, clinical characteristics, and pathogenic bacteria associated with the recurrence of liver abscesses.

Patients and methods: A retrospective analysis was conducted on 436 recently diagnosed patients with pyogenic liver abscess admitted to the Affiliated Hospital of Chengde Medical College between June 2017 and June 2023. Patients with recurrence comprised the observation group, whereas those without recurrence comprised the control group.This analysis included the examination of clinical characteristics, pathogens, drug resistance patterns, and treatment modalities. Additionally, regression analysis was employed to investigate the factors influencing liver abscess recurrence.

Results: Of 436 patients initially diagnosed with pyogenic liver abscess, 58 experienced recurrence. The proportion of Escherichia coli infection was 23.3% in the observation group and 10.3% in the control group, indicating a statistically significant difference. Multivariate analysis identified diabetes mellitus and cerebral infarction as significant risk factors for recurrent pyogenic liver abscess.

Conclusion: In comparison with patients without recurrence, those who experienced recurrent pyogenic liver abscess following initial diagnosis exhibited a higher prevalence of E. coli as a pathogenic bacterium. In addition, a history of diabetes mellitus and cerebral infarction are high-risk factors for with pyogenic liver abscess recurrence for the first time.

目的:比较分析化脓性肝脓肿复发与不复发患者的临床资料,探讨与肝脓肿复发相关的影响因素、临床特点及病原菌。患者与方法:回顾性分析承德医学院附属医院2017年6月至2023年6月收治的436例近期确诊的化脓性肝脓肿患者。复发患者为观察组,无复发患者为对照组。该分析包括临床特征、病原体、耐药模式和治疗方式的检查。并采用回归分析探讨肝脓肿复发的影响因素。结果:在436例最初诊断为化脓性肝脓肿的患者中,58例复发。观察组大肠杆菌感染比例为23.3%,对照组为10.3%,差异有统计学意义。多因素分析发现糖尿病和脑梗死是复发性化脓性肝脓肿的重要危险因素。结论:与没有复发的患者相比,初次诊断后有化脓性肝脓肿复发的患者表现出更高的大肠杆菌患病率。此外,糖尿病史和脑梗死史是首次发生化脓性肝脓肿复发的高危因素。
{"title":"Etiology, Risk Factors, and Antimicrobial Resistance in Recurrent Pyogenic Liver Abscesses: A Six-Year Analysis.","authors":"JinHua Cui, YaMan Liu, Hua Fu, MiaoHang Cui, JiZhong Li, ZiYu Bai, Jian Li","doi":"10.2147/IDR.S492544","DOIUrl":"https://doi.org/10.2147/IDR.S492544","url":null,"abstract":"<p><strong>Aim: </strong>To perform a comparative analysis of the clinical data of patients with and without recurrent pyogenic liver abscess and explore the influencing factors, clinical characteristics, and pathogenic bacteria associated with the recurrence of liver abscesses.</p><p><strong>Patients and methods: </strong>A retrospective analysis was conducted on 436 recently diagnosed patients with pyogenic liver abscess admitted to the Affiliated Hospital of Chengde Medical College between June 2017 and June 2023. Patients with recurrence comprised the observation group, whereas those without recurrence comprised the control group.This analysis included the examination of clinical characteristics, pathogens, drug resistance patterns, and treatment modalities. Additionally, regression analysis was employed to investigate the factors influencing liver abscess recurrence.</p><p><strong>Results: </strong>Of 436 patients initially diagnosed with pyogenic liver abscess, 58 experienced recurrence. The proportion of <i>Escherichia coli</i> infection was 23.3% in the observation group and 10.3% in the control group, indicating a statistically significant difference. Multivariate analysis identified diabetes mellitus and cerebral infarction as significant risk factors for recurrent pyogenic liver abscess.</p><p><strong>Conclusion: </strong>In comparison with patients without recurrence, those who experienced recurrent pyogenic liver abscess following initial diagnosis exhibited a higher prevalence of <i>E. coli</i> as a pathogenic bacterium. In addition, a history of diabetes mellitus and cerebral infarction are high-risk factors for with pyogenic liver abscess recurrence for the first time.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"15-23"},"PeriodicalIF":2.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infection and Drug Resistance
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1